Operating income
YoY n/m−$340.4M TTM−$156.3M Q3 '26
FY22FY23FY24FY25TTM
Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
GPCR
$20.00+0.81%
Structure Therapeutics Inc. American Depositary SharesStock · HealthcareNasdaq Composite · 0.009% of ONEQ
Head-to-head:Compare with INSM or any ticker →
GPCR financial statements
The full income statement, balance sheet, and cash-flow statement for Structure Therapeutics Inc. American Depositary Shares (GPCR), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Financial overview#
Net income
YoY n/m−$293.9M TTM−$144.8M Q3 '26
FY22FY23FY24FY25TTM
Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS (diluted)
YoY n/m−$4.18 TTM−$1.98 Q3 '26
FY22FY23FY24FY25TTM
Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Operating cash flow
YoY n/m−$271M TTM−$101.7M Q3 '26
FY22FY23FY24FY25TTM
Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Capital expenditure
YoY +131.9%$6.3M TTM$3.6M Q3 '26
FY22FY23FY24FY25TTM
Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Free cash flow
YoY n/m−$277.3M TTM−$105.3M Q3 '26
FY22FY23FY24FY25TTM
Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares (diluted)
YoY +24.6%70.3M TTM72.9M Q3 '26
FY22FY23FY24FY25TTM
Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares outstanding (point-in-time)
2024-09 57.3M2024-12 57.3M2025-03 57.5M2025-06 57.6M2025-09 60.7M2025-12 70.8M2026-03 71.1M2026-06 71.3M2026-09 71.6M+25.0% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | |
| 177M+11.6% | 158M+54.0% | 103M+95.5% | 52.6M | ||
| Research & development | 225M+107.0% | 109M+55.2% | 70.1M+93.7% | 36.2M | |
| Selling, general & administrative | 61.6M+24.6% | 49.4M+51.2% | 32.7M+99.6% | 16.4M | |
| General & administrative | 61.6M+24.6% | 49.4M+51.2% | 32.7M+99.6% | 16.4M | |
| Operating income | -177M-11.6% | -158M-54.0% | -103M-95.5% | -52.6M | |
| Pre-tax income | -141M-15.1% | -122M-36.7% | -89.4M-74.2% | -51.3M | |
| Income tax | 515K+66.1% | 310K+31.4% | 236K+1288.2% | 17.0K | |
| -141M-15.2% | -123M-36.7% | -89.6M-74.6% | -51.3M | ||
| Net income to common | -141M-15.2% | -123M-36.7% | -89.6M-69.6% | -52.8M | |
| -$2.40-2.6% | -$2.34+3.7% | -$2.43+85.3% | -$16.53 | ||
| EPS (basic) | -$2.40-2.6% | -$2.34+3.7% | -$2.43+85.3% | -$16.53 | |
| Weighted-avg shares (basic) | 59.2M+12.5% | 52.6M+43.3% | 36.7M+1049.8% | 3.19M | |
| Weighted-avg shares (diluted) | 59.2M+12.5% | 52.6M+43.3% | 36.7M+1049.8% | 3.19M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | |
| 1.57B+76.2% | 891M+88.2% | 474M+408.8% | 93.1M | ||
| Cash & equivalents | 800M+371.7% | 170M+30.6% | 130M+397.5% | 26.1M | |
| Short-term investments | 647M-9.4% | 714M+111.5% | 338M+421.3% | 64.8M | |
| Cash & short-term investments | 1.45B+63.7% | 884M+89.1% | 467M | — | |
| Prepaid expenses | 24.1M+213.3% | 7.69M+22.4% | 6.29M+179.6% | 2.25M | |
| 1.58B+75.3% | 903M+87.4% | 482M+392.6% | 97.8M | ||
| Property, plant & equipment | 6.65M+91.3% | 3.48M+7.7% | 3.23M+213.1% | 1.03M | |
| Operating lease right-of-use | 6.25M+76.7% | 3.54M-31.2% | 5.14M+1860.3% | 262K | |
| Other non-current assets | 717K-86.0% | 5.11M+11246.7% | 45.0K-98.7% | 3.46M | |
| 63.3M+75.7% | 36.0M+45.6% | 24.7M+90.2% | 13.0M | ||
| Accounts payable | 13.9M+72.8% | 8.02M+69.2% | 4.74M-21.1% | 6.01M | |
| Current lease liability | 2.88M+69.5% | 1.70M+17.9% | 1.44M+453.8% | 260K | |
| 67.5M+75.5% | 38.5M+32.5% | 29.1M+123.3% | 13.0M | ||
| Non-current lease liability | 3.61M+66.8% | 2.16M-46.1% | 4.01M | — | |
| Operating lease liability (total) | 6.49M+68.0% | 3.86M-29.2% | 5.45M | — | |
| Other non-current liabilities | 647K+114.2% | 302K+1.3% | 298K | — | |
| 1.52B+75.3% | 865M+90.9% | 453M+493.4% | -115M | ||
| Common stock | 21.0K+23.5% | 17.0K+21.4% | 14.0K+1300.0% | 1.00K | |
| Additional paid-in capital | 1.99B+66.4% | 1.19B+81.0% | 659M+34205.2% | 1.92M | |
| Retained earnings | -470M-42.9% | -329M-59.3% | -207M-76.6% | -117M | |
| Accumulated other comprehensive income | 1.05M+15.3% | 914K+75.4% | 521K+573.6% | -110K | |
| Total equity incl. non-controlling | 1.52B+75.3% | 865M+90.9% | 453M | — | |
| Total liabilities & equity | 1.58B+75.3% | 903M+87.4% | 482M+392.6% | 97.8M | |
| Common shares issued | 70.8M+23.7% | 57.3M+23.4% | 46.4M+1222.5% | 3.51M | |
| Common shares outstanding | 70.8M+23.7% | 57.3M+23.4% | 46.4M+1222.5% | 3.51M | |
| Shares outstanding (cover) | 70.8M+23.5% | 57.3M+23.1% | 46.6M | — | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | |
| -222M-90.5% | -117M-46.7% | -79.5M-72.4% | -46.1M | ||
| Depreciation & amortization | 1.33M+34.4% | 992K+236.3% | 295K+6.5% | 277K | |
| Share-based compensation | 29.0M+54.3% | 18.8M+129.4% | 8.19M+225.8% | 2.51M | |
| Change in payables | 4.76M+44.1% | 3.31M+484.5% | -860K-139.9% | 2.15M | |
| 89.8M+125.0% | -359M-33.8% | -268M-332.1% | -62.1M | ||
| Capital expenditure | 3.61M+180.2% | 1.29M-40.5% | 2.17M+1298.1% | 155K | |
| Free cash flow | -226M-91.5% | -118M-44.4% | -81.7M-76.5% | -46.3M | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | |
| 763M+48.0% | 515M+14.1% | 452M+1456.3% | 29.0M | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | — | 515M | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | — | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net change in cash | 630M+1486.5% | 39.7M-61.7% | 104M+230.9% | -79.2M | |
| Income taxes paid | 634K+71.4% | 370K+2983.3% | 12.0K | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | |
| Market cap | 4.93B+217.1% | 1.55B-17.8% | 1.89B | — | |
| P/B | 3.2×+80.9% | 1.8×-81.7% | 9.8× | — | |
| Source filing | 10-K | 10-K | 10-K | 10-K |
CEO pay#
As charts →| Fiscal year | CEO | Total, as reported | Actually paid | Other executives, average | $100 in the stock | $100 in peers |
|---|---|---|---|---|---|---|
| FY2025 | Raymond Stevens, Ph.D. | $8.4M | $36.2M | $3M | $267.50 | $134.82 |
| FY2024 | — | $5.7M | $1.7M | $3.6M | $104.31 | $101.04 |
| FY2023 | — | $7.4M | $22.1M | $2.2M | $156.77 | $101.62 |
From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.
About this data
Source: GPCR’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all GPCR filings on SEC EDGAR → Not investment advice.
Head-to-head:Compare with INSM or any ticker →